Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease by Seini Moimoi | Jan 30, 2020 | Portfolio News
Kala Pharmaceuticals Announces Completion of Enrollment of Stride 3 Trial for Eysuvis (KPI-121 0.25%) for Dry Eye Disease by Seini Moimoi | Jan 15, 2020 | Portfolio News
Inflazome IP Portfolio Strengthened with Patents Granted in US and Europe by Seini Moimoi | Jan 13, 2020 | Portfolio News
Aptinyx Announces Pricing of Public Offering of Common Stock by Seini Moimoi | Jan 10, 2020 | Portfolio News
